Cue Biopharma Inc (CUE) - News Archive

Pioneering Partnership: Boehringer Ingelheim Teams Up with Cue Biopharma to Revolutionize Autoimmune Disease TreatmentsIn an inspiring display of innovative collaboration, two biopharmaceutical powerhouses, Boehringer I...

Revolutionizing Cancer Treatment: Cue Biopharma Unveils Promising Data from Phase 1 Trials of CUE-101 and CUE-102 at SITC Annual Meeting BOSTON, Nov. 08, 2024 - Cue Biopharma, Inc. (Nasdaq: CUE), a leading clinical-stag...

Cue Biopharma Moves Forward with Public Offering to Fuel T Cell Therapeutics DevelopmentBOSTON, Sept. 26, 2024 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical firm known for its innovative approach...

Cue Biopharma Announces Public Offering of Common Stock and Warrants Amid Strategic Focus on Autoimmune TherapeuticsBy BOSTON, September 26, 2024 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical com...

In the kaleidoscopic landscape of biopharmaceuticals, companies are increasingly faced with the need to strategically prioritize their development programs to maximize value creation while minimizing risk. Cue Biopharma...

As the healthcare industry continues to evolve and innovate, Cue Biopharma Inc (CUE) has emerged as a significant player in the field of biopharmaceuticals. With a focus on developing novel biologics to treat cancer and...

Interim Data Shows Promise: Cue Biopharma’s CUE-101 in Advanced HPV+ Head and Neck Cancer BOSTON, June 4, 2024 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical innovator, has announced significant,...

Cue Biopharma, Inc. (Nasdaq: CUE), a pioneering clinical-stage biopharmaceutical company focused on the development of disease-specific T-cell modulating therapeutic biologics, is proud to announce that their lead clini...